1. Home
  2. VIGL vs ARMP Comparison

VIGL vs ARMP Comparison

Compare VIGL & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VIGL
  • ARMP
  • Stock Information
  • Founded
  • VIGL 2020
  • ARMP N/A
  • Country
  • VIGL United States
  • ARMP United States
  • Employees
  • VIGL N/A
  • ARMP N/A
  • Industry
  • VIGL Biotechnology: Pharmaceutical Preparations
  • ARMP Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • VIGL Health Care
  • ARMP Health Care
  • Exchange
  • VIGL Nasdaq
  • ARMP Nasdaq
  • Market Cap
  • VIGL 89.3M
  • ARMP 80.0M
  • IPO Year
  • VIGL 2022
  • ARMP N/A
  • Fundamental
  • Price
  • VIGL $2.76
  • ARMP $1.95
  • Analyst Decision
  • VIGL Strong Buy
  • ARMP Strong Buy
  • Analyst Count
  • VIGL 5
  • ARMP 1
  • Target Price
  • VIGL $21.00
  • ARMP $7.00
  • AVG Volume (30 Days)
  • VIGL 2.7M
  • ARMP 8.0K
  • Earning Date
  • VIGL 03-25-2025
  • ARMP 03-20-2025
  • Dividend Yield
  • VIGL N/A
  • ARMP N/A
  • EPS Growth
  • VIGL N/A
  • ARMP N/A
  • EPS
  • VIGL N/A
  • ARMP N/A
  • Revenue
  • VIGL N/A
  • ARMP $5,467,000.00
  • Revenue This Year
  • VIGL N/A
  • ARMP $23.87
  • Revenue Next Year
  • VIGL N/A
  • ARMP N/A
  • P/E Ratio
  • VIGL N/A
  • ARMP N/A
  • Revenue Growth
  • VIGL N/A
  • ARMP 34.92
  • 52 Week Low
  • VIGL $1.49
  • ARMP $1.80
  • 52 Week High
  • VIGL $6.06
  • ARMP $4.48
  • Technical
  • Relative Strength Index (RSI)
  • VIGL 70.15
  • ARMP 42.06
  • Support Level
  • VIGL $2.54
  • ARMP $1.89
  • Resistance Level
  • VIGL $2.88
  • ARMP $2.08
  • Average True Range (ATR)
  • VIGL 0.22
  • ARMP 0.10
  • MACD
  • VIGL 0.03
  • ARMP -0.01
  • Stochastic Oscillator
  • VIGL 85.19
  • ARMP 18.18

About VIGL Vigil Neuroscience Inc.

Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.

About ARMP Armata Pharmaceuticals Inc.

Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.

Share on Social Networks: